The Claim
In patients with advanced non-small cell lung cancer, six weeks of omega-3 fatty acid supplementation does not significantly alter plasma levels of tumor necrosis factor-alpha or prostaglandin E2.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with advanced non-small cell lung cancer, taking omega-3 fatty acid supplements for six weeks does not change the levels of two specific inflammatory markers in the blood.
See the scientific wording
In patients with advanced non-small cell lung cancer, omega-3 fatty acid supplementation does not significantly alter plasma levels of tumor necrosis factor-alpha or prostaglandin E2 after six weeks of treatment, indicating that its anti-inflammatory effect is selective and does not broadly suppress all inflammatory mediators.
Omega-3 fats get into cell membranes and change how cells make signaling molecules. This stops some inflammatory signals like IL-6 and CRP from being made, but does not stop others like TNF-alpha and PGE2. The cells keep making those two even when omega-3s are present.
What the research says
1 studyOmega-3 supplements lowered two inflammation markers (CRP and IL-6) in lung cancer patients, but didn’t change two others (TNF-alpha and PGE2). This means they don’t shut down all inflammation—just some parts.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.